Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have been given an average rating of “Buy” by the eight brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $4.46.

SYN has been the topic of several analyst reports. ValuEngine lowered shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. William Blair restated an “outperform” rating and set a $5.00 price target on shares of Synthetic Biologics in a research report on Monday, May 22nd. Finally, Zacks Investment Research raised shares of Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a report on Wednesday, May 10th.

Shares of Synthetic Biologics (NYSEMKT SYN) traded down 3.6505% on Monday, hitting $0.5094. 1,188,133 shares of the stock traded hands. The stock has a 50 day moving average of $0.61 and a 200 day moving average of $0.70. The company’s market cap is $62.09 million. Synthetic Biologics has a one year low of $0.41 and a one year high of $1.94.

Synthetic Biologics (NYSEMKT:SYN) last released its quarterly earnings data on Thursday, May 4th. The company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.05. Equities analysts anticipate that Synthetic Biologics will post ($0.25) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another website, it was illegally copied and reposted in violation of international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/07/10/synthetic-biologics-inc-nysemktsyn-given-average-recommendation-of-buy-by-brokerages.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in Synthetic Biologics during the fourth quarter valued at approximately $356,000. Bank of New York Mellon Corp increased its stake in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares during the period. Finally, UBS Group AG increased its stake in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares during the period.

Synthetic Biologics Company Profile

Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.

Analyst Recommendations for Synthetic Biologics (NYSEMKT:SYN)

Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.